A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Non-small Cell Lung Cancer
Squamous Cell Carcinoma (Skin)
Renal Cell Carcinoma
Merkel Cell Carcinoma
Triple Negative Breast Cancer
Head and Neck Squamous Cell Carcinoma
Gastric Cancer/Gastroesophageal Junction Cancer
High Grade Serous Ovarian Carcinoma

Interventions

DRUG: AZD6750
DRUG: rilvegostomig

Sponsor

AstraZeneca